BPH and Inflammation: Pharmacological Effects of Permixon on Histological and Molecular Inflammatory Markers. Results of a Double Blind Pilot Clinical Assay
- 1 November 2003
- journal article
- clinical trial
- Published by Elsevier in European Urology
- Vol. 44 (5), 549-555
- https://doi.org/10.1016/s0302-2838(03)00368-3
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- VASCULAR ENDOTHELIAL GROWTH FACTOR EXPRESSION AND TUMOR ANGIOGENESIS ARE REGULATED BY ANDROGENS IN HORMONE RESPONSIVE HUMAN PROSTATE CARCINOMA: : EVIDENCE FOR ANDROGEN DEPENDENT DESTABILIZATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR TRANSCRIPTSJournal of Urology, 2001
- Cell kinetics and differentiation after hormonal-induced prostatic hyperplasia in the dogThe Prostate, 2000
- Effects of long-term treatment withSerenoa repens (Permixon®) on the concentrations and regional distribution of androgens and epidermal growth factor in benign prostatic hyperplasiaThe Prostate, 1998
- Effect of the lipidic lipidosterolic extract of Serenoa repens (Permixon®) on the ionophore A23187-stimulated production of leukotriene B4 (LTB4) from human polymorphonuclear neutrophilsProstaglandins, Leukotrienes & Essential Fatty Acids, 1997
- Comparison of phytotherapy (Permixon®) with finasteride in the treatment of benign prostate hyperplasia: A randomized international study of 1,098 patientsThe Prostate, 1996
- Stromal Nodules in Benign Prostatic HyperplasiaEuropean Urology, 1996
- An immunohistochemical characterisation of the inflammatory cell infiltrate in benign and malignant prostatic diseaseBritish Journal of Cancer, 1990
- Patterns of Inflammation in Prostatic Hyperplasia: A Histologic and Bacteriologic StudyJournal of Urology, 1979
- Benign Hypertrophy of the Prostate. A Morphological StudyJournal of Urology, 1943
- Inflammation of the Prostate GlandJournal of Urology, 1937